BiotechTube

warfarin + omefas + omega-3-acid ethyl esters

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia

Trial Timeline

Aug 1, 2011 → Oct 1, 2011

NCT ID
NCT01431690

About warfarin + omefas + omega-3-acid ethyl esters

warfarin + omefas + omega-3-acid ethyl esters is a phase 1 stage product being developed by AstraZeneca for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01431690. Target conditions include Hypertriglyceridemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01431690Phase 1Completed

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors
ProductCompanyStageHype Score
LY3875383 + PlaceboEli LillyPhase 1
33
ZYH7 + ZYH7 + ZYH7 + FenofibrateZydus LifesciencesPhase 2
52
Solbinsiran + PlaceboEli LillyPhase 2
52
Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3
77
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3
77
rosuvastatinAstraZenecaApproved
85
Simvastatin + acetylsalicylic acid (ASA) + omefasAstraZenecaPhase 1
33
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3
77
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)AstraZenecaPhase 2
52
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hoursAstraZenecaPhase 1
33
placebo + omefas + omefas + omefasAstraZenecaPhase 2/3
65
Epanova + LovazaAstraZenecaPhase 1
33
Epanova + Olive OilAstraZenecaPhase 3
77
AZD0585 + AZD0585 placeboAstraZenecaPhase 3
77
ABT-143 + simvastatinAstraZenecaPhase 3
77
MaravirocPfizerPhase 1
32
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
76
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)Mochida PharmaceuticalPhase 3
76
IcosapentMochida PharmaceuticalPhase 3
76
REGN1500 + placeboRegeneron PharmaceuticalsPhase 1
32

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85